Potential Roles for First-Line Targeted Therapy for Advanced Melanoma
Source: Cancer Network, December 2024
Panelists discuss how first-line targeted therapy for advanced melanoma, particularly BRAF and MEK inhibitors, may offer significant benefits in patients with BRAF-mutant tumors, emphasizing rapid response and the potential for combination with immunotherapy to improve long-term outcomes.
